FDA accelerated approval of Hepcludex to address serious unmet need in US HDV market, says GlobalData

FDA accelerated approval of Hepcludex significant milestone for US HDV market

Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone for the HDV market.The post FDA accelerated approval of Hepcludex significant milestone for US HDV market appeared first on Clinical Trials Arena.

FDA accelerated approval of Hepcludex to address serious unmet need in US HDV market, says GlobalData

The US Food and Drug Administration (FDA) has recently granted accelerated approval to Gilead Sciences’ antiviral, Hepcludex (bulevirtide-gmod), for the treatment of adults with chronic hepatitis delta virus (HDV) infection without cirrhosis or with compensated cirrhosis. Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone for HDV patients and addressing a serious unmet need in the H…